Abstract:Targeting proteins' enzymatic functions with small molecule inhibitors, as well as functions of receptor proteins with small-molecule agonists and antagonists, were the major forms of small-molecule drug development. These small-molecule modulators are based on a conventional occupancy-driven pharmacological approach. For proteome space traditionally considered undruggable by small-molecule modulators, such as enzymes with scaffolding functions, transcription factors, and proteins that lack well-defined binding pockets for small molecules, targeted protein degraders offer the opportunity to drug the proteome with an event-driven pharmacological approach. A degrader molecule, either PROTAC or molecular glue, brings the protein of interest (POI) and E3 ubiquitin ligase in close proximity and engages the ubiquitin-proteasome system (UPS), the cellular waste disposal system for the degradation of the POI. For the development of targeted protein degraders to meet therapeutic needs, several aspects will be considered, namely, the selective degradation of disease-causing proteins, the oral bioavailability of degraders beyond Lipinski's rule of five (bRo5) scope, demands of new E3 ubiquitin ligases and molecular glue degraders, and drug resistance of the new drug modality. This review will illustrate several under-discussed key considerations in targeted protein degradation drug discovery and development: 1) the contributing factors for the selectivity of PROTAC molecules and the design of PROTACs to selectively degrade synergistic pathological proteins; 2) assay development in combination with a multi-omics approach for the identification of new E3 ligases and their corresponding ligands, as well as molecular glue degraders; 3) a molecular design to improve the oral bioavailability of bRo5 PROTACs, and 4) drug resistance of degraders.

Current Challenges in Small Molecule Proximity-Inducing Compound Development for Targeted Protein Degradation Using the Ubiquitin Proteasomal System

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

Bivalent Ligands for Protein Degradation in Drug Discovery

Targeting Cullin-RING Ubiquitin Ligases and the Applications in PROTACs

Targeted protein degradation: expanding the toolbox

Targeted Degradation of 53BP1 Using Ubiquitin Variant Induced Proximity

Investigating Protein Degradability through Site-Specific Ubiquitin Ligase Recruitment

[Protein induced proximity and targeted degradations by new degraders: concepts, developments, challenges for clinical applications]

Key Considerations in Targeted Protein Degradation Drug Discovery and Development

Small Molecule PROTACs in Targeted Therapy: an Emerging Strategy to Induce Protein Degradation.

Targeted protein degradation via intramolecular bivalent glues

Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation

Opportunities and Challenges of Small Molecule Induced Targeted Protein Degradation

Targeted protein degradation: from mechanisms to clinic

Advancing targeted protein degradation for cancer therapy

Molecular glue-mediated targeted protein degradation: A novel strategy in small-molecule drug development

Discovery of E3 Ligase Ligands for Target Protein Degradation

PROTACs: Emerging Targeted Protein Degradation Approaches for Advanced Druggable Strategies

Targeted Kinase Degradation via the KLHDC2 Ubiquitin E3 Ligase

Emerging TACnology: Heterobifunctional Small Molecule Inducers of Targeted Posttranslational Protein Modifications

Targeted Modulation of E3 Ligases Using Engineered Ubiquitin Variants.